Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | STK4 | Q13043 | 2/20 | 0.33 |
| ▸ | STK3 | Q13188 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1598149 | 0.79 | CHEK1 (0.66) | CHEK1TRPA1NOTUMAURKAAKT1 | |
| SCHEMBL22912722 | 0.79 | CHEK1 (0.66) | CHEK1TRPA1NOTUMAURKAAKT1 | |
| SCHEMBL31329069 | 0.79 | CHEK1 (0.66) | CHEK1TRPA1NOTUMAURKAAKT1 | |
| SCHEMBL153752 | 0.78 | CHEK1 (0.63) | CHEK1TRPA1NOTUMAURKAAKT1 | |
| SCHEMBL397485 | 0.78 | CHEK1 (0.63) | CHEK1TRPA1AURKAMAPK1STK3 | |
| SCHEMBL2323682 | 0.78 | CHEK1 (0.63) | CHEK1TRPA1NOTUMAURKAAKT1 | |
| SCHEMBL2537071 | 0.76 | CHEK1 (0.61) | CHEK1TRPA1AURKAAKT1MAPK1 | |
| SCHEMBL7887899 | 0.76 | CHEK1 (0.61) | CHEK1TRPA1NOTUMAURKAMAPK1 | |
| SCHEMBL357993 | 0.76 | CHEK1 (0.61) | CHEK1TRPA1NOTUMAURKAAKT1 | |
| SCHEMBL5019486 | 0.76 | CHEK1 (0.61) | CHEK1TRPA1NOTUMAURKAAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1072 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117088886-A | Novel pyrrolo [2,3-d ] pyrimidine derivative containing coumarin, and preparation method and application thereof | 山东省药学科学院 | 2023-11-21 | — | — | CN | claimed |
| CN-115340557-A | Synthesis method of 4-chloro-5-iodo-7-methyl-7H-pyrrolo [2,3-d ] pyrimidine | 安徽大学 | 2022-11-15 | — | — | CN | claimed |
| CN-114907348-B | Preparation method of 4-chloro-5-iodo-7H-pyrrolo [2,3-d ] pyrimidine | 济南宣正药业有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-114907348-A | Preparation method of 4-chloro-5-iodo-7H-pyrrolo [2,3-d ] pyrimidine | 济南宣正药业有限公司 | 2022-08-16 | — | — | CN | claimed |
| CN-112851719-A | Method for synthesizing giardiamycin | 康化（上海）新药研发有限公司 | 2021-05-28 | — | — | CN | claimed |
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | claimed |
| EP-1682564-A1 | METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-26 | — | — | EP | claimed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | claimed |
| WO-2005044835-A1 | METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2005-05-19 | — | — | WO | claimed |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-12552826-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4687884-A2 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4687883-A2 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-1994017803-A9 | ADENOSINE KINASE INHIBITORS | — | 1994-09-29 | — | — | WO | disclosed |
| WO-1994018215-A1 | ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1994017803-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1992012718-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| EP-0496617-A1 | Adenosine kinase inhibitors | GENSIA, INC. (US) | 1992-07-29 | — | — | EP | disclosed |
| US-4968686-A | DECREASED CYTOTOXICITY; CYTOMEGALO AND HERPEX SIMPLEX VIRUSES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1990-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | CHEK1 364/4885TRPA1 4124/4885NOTUM 4818/4885 |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | HAVCR2, NR4A3, NR2C2 | CHEK1 4549/4885TRPA1 4796/4885NOTUM 4684/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | CHEK1 1951/4885TRPA1 44/4885NOTUM 3035/4885 |
| US-12552826-B2 | PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | CHEK1 202/4885TRPA1 4469/4885NOTUM 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.